IPHA
Innate Pharma S.A.
NASDAQ · Healthcare · Biotechnology · FR
$2.08
−1.42%Institutional positioning
13F filings over the trailing two quarters
New 2Increased 0Reduced 6Sold out 9
| Filer | Action | Shares | Filed |
|---|---|---|---|
| LION POINT CAPITAL, LP | Unchanged | 81,151 | May 15, 2026 |
| MORGAN STANLEY | Reduced | 43,524 | May 15, 2026 |
| JANE STREET GROUP, LLC | Reduced | 43,365 | May 12, 2026 |
| CITADEL ADVISORS LLC | New Position | 12,441 | Sep 2, 2026 |
| MILLENNIUM MANAGEMENT LLC | Reduced | 10,064 | May 15, 2026 |
| RHUMBLINE ADVISERS | Reduced | 4,734 | May 12, 2026 |
| UBS GROUP AG | Reduced | 861 | May 5, 2026 |
| GAMMA INVESTING LLC | Reduced | 240 | Apr 6, 2026 |
| FARTHER FINANCE ADVISORS, LLC | Unchanged | 10 | Apr 7, 2026 |
| CAITONG INTERNATIONAL ASSET MANAGEMENT CO., LTD | New Position | 2 | May 11, 2026 |
| Lion Point Capital, LP | Sold Out | 0 | May 15, 2026 |
| RHUMBLINE ADVISERS | Sold Out | 0 | May 12, 2026 |
| MORGAN STANLEY | Sold Out | 0 | May 15, 2026 |
| GAMMA Investing LLC | Sold Out | 0 | Apr 6, 2026 |
| Farther Finance Advisors, LLC | Sold Out | 0 | Apr 7, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings